Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.

Conclusions: Analysis of the reports with patients treated with sunitinib, sorafenib, axitinib, and cabozantinib showed a clear prevalence of stomatitis grade 1 or grade 2. These data differ from those of patients treated with conventional chemotherapy in which mucositis is predominantly of grade 3 or grade 4.
PMID: 29992147 [PubMed - in process]

Source: Biomed Res - July 13, 2018 Category: Research Authors: Arena C, Troiano G, De Lillo A, Testa NF, Lo Muzio L Tags: Biomed Res Int Source Type: research